Daily Anesthesiology Research Analysis
Three studies with strong implications for anesthesiology practice stand out today: a randomized trial shows prophylactic norepinephrine at induction reduces intraoperative hypotension and postoperative complications in major abdominal surgery; a large systematic review/meta-analysis confirms sugammadex accelerates reversal and lowers pulmonary and cardiac-related adverse events versus neostigmine; and a multicenter RCT demonstrates remimazolam offers superior hemodynamic stability and faster re
Summary
Three studies with strong implications for anesthesiology practice stand out today: a randomized trial shows prophylactic norepinephrine at induction reduces intraoperative hypotension and postoperative complications in major abdominal surgery; a large systematic review/meta-analysis confirms sugammadex accelerates reversal and lowers pulmonary and cardiac-related adverse events versus neostigmine; and a multicenter RCT demonstrates remimazolam offers superior hemodynamic stability and faster recovery than propofol for elderly hypertensive patients during gastroenteroscopy.
Research Themes
- Intraoperative hemodynamic optimization and hypotension prevention
- Neuromuscular blockade reversal and postoperative safety
- Sedation strategies for vulnerable elderly patients
Selected Articles
1. Early Use of Norepinephrine in High-risk Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial.
In high-risk major abdominal surgery, starting a titrated norepinephrine infusion at induction markedly reduced intraoperative hypotension and lowered the 30-day composite complication rate versus reactive ephedrine boluses. Pulmonary complications were also significantly fewer with norepinephrine.
Impact: This RCT directly addresses postinduction hypotension, a prevalent and modifiable risk, demonstrating improved perioperative outcomes with a simple, scalable intervention.
Clinical Implications: Consider protocolized, titrated norepinephrine infusion starting at induction for older/high-risk patients undergoing major abdominal surgery to prevent hypotension and potentially reduce pulmonary and overall complications.
Key Findings
- Titrated norepinephrine started at induction reduced intraoperative hypotension versus ephedrine (15% vs 74%; P<0.001).
- 30-day composite complications were lower with norepinephrine (44% vs 58%; RR 0.58, 95% CI 0.40–0.83; P=0.004).
- Pulmonary complications were significantly reduced with norepinephrine (17% vs 31%; RR 0.46, 95% CI 0.29–0.70; P<0.001).
Methodological Strengths
- Randomized controlled design with intention-to-treat analysis (n=473).
- Blinded outcome assessment and prespecified endpoints.
Limitations
- Single-center design may limit generalizability.
- Composite primary outcome mixes heterogeneous complications.
Future Directions: Multicenter pragmatic RCTs testing protocolized induction norepinephrine across diverse surgeries and risk strata; comparative effectiveness versus alternative vasopressors and closed-loop blood pressure management.
BACKGROUND: Intraoperative hypotension is a strong predictor of adverse outcomes in major abdominal surgery. However, data on the occurrence of intraoperative hypotension during the induction of general anesthesia are scarce. We hypothesized that early prevention of postinduction hypotension using a vasopressor could reduce postoperative adverse outcomes. METHODS: In this single-center randomized trial at Amiens Hospital University (Amiens, France), adults older than 50 yr with American Society of Anesthesiologists (Schaumburg, Illinois) Physical Status II or greater undergoing major abdominal surgery were assigned to ephedrine or norepinephrine groups. In the ephedrine group, titration with iterative boluses of ephedrine (3 mg · ml -1 ) was performed at the induction if intraoperative hypotension occurred. In the norepinephrine group, continuous intravenous injection of norepinephrine (0.016 mg · ml -1 ) was started at a rate of 0.48 mg · h -1 from the induction of anesthesia and was titrated if intraoperative hypotension occurred. The primary endpoint was any medico-surgical complication within 30 days (Clavien-Dindo score of 1 or greater). Secondary endpoints included hospital stay length, acute kidney injury, 1-month mortality, and cardiovascular, respiratory, neurologic, and infectious complications. Results were assessed by blinded evaluators. RESULTS: A total of 500 patients were randomized, and 473 were included in the intention-to-treat analysis. The cumulative episodes of intraoperative hypotension were significantly lower in the norephedrine group in comparison to the ephedrine group (respectively, 35 [15%] vs. 176 [74%]; P < 0.001). The primary endpoint occurred in 137 patients (58%) in the ephedrine group and 103 patients (44%) in the norepinephrine group (relative risk, 0.58 [0.40 to 0.83]; P = 0.004). No significant differences were observed in secondary endpoints, except for pulmonary complications, which were lower in the norepinephrine group than in the ephedrine group (respectively; 40 [17%] vs. 74 [31%]; relative risk, 0.46 [0.29; 0.70]; P < 0.001). CONCLUSIONS: Prophylactic titrated norepinephrine infusion to prevent postinduction hypotension was more effective than repeated ephedrine boluses and may reduce postoperative complications in major abdominal surgery.
2. Effect of Remimazolam versus Propofol on Hemodynamics in Elderly Hypertensive Patients Undergoing Gastroenteroscopy: A Multicenter, Randomized Controlled Clinical Trial.
In elderly hypertensive patients undergoing gastroenteroscopy, remimazolam conferred better hemodynamic stability than propofol and enabled faster recovery, with continuous noninvasive arterial pressure monitoring supporting reduced hypotension and favorable profiles across MAP, CO, and SVR.
Impact: Addresses a high-risk sedation scenario with a pragmatic multicenter RCT, offering an alternative to propofol that may reduce hypotension in vulnerable patients.
Clinical Implications: For elderly hypertensive patients undergoing endoscopy, remimazolam-based sedation may be preferred to minimize hypotension and accelerate recovery, particularly in settings emphasizing hemodynamic stability.
Key Findings
- Multicenter, single-blind RCT (n=220) comparing remimazolam vs propofol with standardized opioid co-administration and CNAP monitoring.
- Remimazolam was associated with significantly fewer hypotensive events and faster recovery.
- Hemodynamic parameters (MAP, CO, SVR) favored greater stability under remimazolam.
Methodological Strengths
- Multicenter randomized design with objective continuous arterial pressure monitoring.
- Standardized dosing regimens and predefined recovery endpoints.
Limitations
- Single-blind design may introduce performance bias.
- Endoscopy setting limits generalizability to other procedures and deeper sedation levels.
Future Directions: Head-to-head trials across diverse procedures and ASA strata, cost-effectiveness analyses, and evaluation in patients with severe cardiac disease or polypharmacy.
PURPOSE: This study aimed to compare the effects of remimazolam and propofol on hemodynamics in elderly hypertensive patients undergoing gastroenteroscopy. METHODS: In this multicenter, single-blind, randomized clinical trial, 220 hypertensive patients (65-75 years) scheduled for gastroenteroscopy were randomly assigned to receive either remimazolam (group R, n=110; 0.3 mg/kg induction followed by 0.2-1 mg/kg/h maintenance) or propofol (group P, n=110; 1.5 mg/kg induction followed by 2-6 mg/kg/h maintenance), both combined with 0.1 μg/kg sufentanil. Flumazenil or placebo was administered for reversal. Hemodynamics were monitored via Continuous Non-Invasive Arterial Pressure (CNAP). The primary outcomes were hypotension incidence and hemodynamic parameters [mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), and systemic vascular resistance (SVR)]; secondary outcomes included the incidence of other adverse events and recovery time. RESULTS: Group R exhibited significantly lower incidences of hypotension (72.7% vs 37.3%, CONCLUSION: Remimazolam provides superior hemodynamic stability and faster recovery compared to propofol in elderly hypertensive patients undergoing gastroenteroscopy, establishing it as a safer sedation option for this vulnerable patient population. TRIAL NUMBER AND REGISTRY URL: Registration number, ChiCTR2400083757; https://www.chictr.org.cn/showproj.html?proj=214795.
3. Sugammadex vs neostigmine in post-anesthesia recovery: A systematic review and meta-analysis.
Across 35 RCTs and 2 large observational cohorts, sugammadex provided faster reversal, shorter extubation, and lower rates of residual blockade compared with neostigmine, while also reducing PONV, postoperative pulmonary complications, and bradycardia. No clear differences were seen in overall recovery quality or postoperative cognition.
Impact: Synthesizes high-level evidence confirming clinically meaningful safety and efficiency advantages of sugammadex over neostigmine, informing perioperative protocols.
Clinical Implications: Prefer sugammadex over neostigmine to minimize residual blockade, shorten extubation, and reduce PONV and pulmonary complications, especially in patients at risk for respiratory adverse events.
Key Findings
- Sugammadex accelerated recovery to TOFR ≥0.9 (SMD -3.45, 95% CI -4.42 to -2.48) and shortened extubation time (SMD -1.44, 95% CI -2.02 to -0.85).
- Residual neuromuscular blockade incidence was markedly reduced (RR 0.18, 95% CI 0.07–0.47).
- Postoperative complications were lower: PONV (RR 0.64), pulmonary complications (RR 0.62), and bradycardia (RR 0.32).
Methodological Strengths
- Comprehensive meta-analysis of 35 RCTs with consistent directionality of effects.
- Assessment of clinically relevant adverse outcomes beyond pharmacodynamic endpoints.
Limitations
- Heterogeneity in dosing, anesthetic techniques, and outcome definitions across trials.
- Primary journal is mid-tier; some included studies may have variable risk of bias.
Future Directions: Patient-level meta-analyses to refine risk-benefit in specific subgroups (e.g., obesity, OSA, thoracic surgery) and cost-effectiveness in resource-variable settings.
Residual neuromuscular blockade (RNB) is linked to an increased risk of perioperative adverse events. This study systematically evaluates the impact of neuromuscular blockade antagonists on postoperative complications and quality of recovery in surgical patients. We conducted a systematic review and meta-analysis to compare the efficacy of sugammadex and neostigmine. Comprehensive searches were performed across medical databases, including Web of Science, PubMed, Embase, and the Cochrane Library, with a final search date of April 6, 2025. A total of thirty-five randomized controlled trials (RCTs) involving 4,275 patients, along with two retrospective studies comprising 49,642 participants, met the inclusion criteria. The meta-analysis revealed that sugammadex facilitated faster reversal of RNB compared to neostigmine, as indicated by a quicker recovery to a train-of-four ratio (TOFR) ≥ 0.9 (standardized mean difference [SMD] -3.45; 95% confidence interval [CI], -4.42 to -2.48), a shorter extubation time (SMD -1.44; 95% CI, -2.02 to -0.85), and a decreased incidence of RNB (risk ratio [RR] 0.18; 95% CI, 0.07 to 0.47). Moreover, sugammadex significantly reduced postoperative complications compared to neostigmine, including the incidence of postoperative nausea and vomiting (PONV) (RR 0.64; 95% CI, 0.46 to 0.88), postoperative pulmonary complications (PPCs) (RR 0.62; 95% CI, 0.38 to 0.99), and bradycardia (RR 0.32; 95% CI, 0.20 to 0.50). In conclusion, sugammadex provides a faster reversal of neuromuscular blockade compared to neostigmine and is associated with a reduction in postoperative complications. However, this expedited reversal does not result in measurable improvements in overall recovery quality, nor do either sugammadex or neostigmine significantly affect postoperative cognitive function.